Shots: The P-III OA (A4091056) study involves evaluation of Tanezumab (2.5, 2.5/5 mg SC) vs PBO in 698 patients in ratio (1:1:1) with OA of the knee or hip for 16wks. P-III OA (A4091056) study results: WOMAC Pain (-3.2, -3.4 vs -2.6); Reduction from baseline ≥30/50/70/90% (68.0% ,54.5% ,34.6%, 14.7%: 70.4%, 57.1%, 36.5%, 14.2% vs […]Read More
